References

S
Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012;43(4):424-432.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatol. 2006;43(6):1317-1325.
Sterling RK, Zeuzem S, Wetzel T, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: results from the HCV-TARGET study. International Liver Congress. 2019.
Stewart ZA, Stern J, NM A, et al. Clinical and financial implications of 2 treatment strategies for donor-derived hepatitis C infections. Transplant Direct. 2021;7(10):e762. doi:10.1097/TXD.0000000000001222.
Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. O'Driscoll PT, Golub ET, Kapadia F, et al., eds. Clin Infect Dis. 2005;40(Suppl 5):S304-S312.
Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2016;65(2):426-438.
Su F, Green PK, Ioannou GN. The Association association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017;65(2):426-438.
Sulkowski MS, Sherman KE, Dieterich D, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
Sulkowski M, Telep LE, Colombo M, et al. Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. Aliment Pharmacol Ther. 2022;55(9):1169-1178. doi:10.1111/apt.16830 .
Sulkowski MS, Hézode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial. Vierling JM, Mallolas J, Pol S, et al., eds. Lancet. 2015;285(9973):1087-1097. doi:10.1016/S0140-6736(14)61793-1.
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Fessel WJ, Mounzer K, Shuhart M, et al., eds. JAMA. 2014;312(4):353-361.
Sulkowski M, Cheng WH, Marx S, Y Gonzalez S, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther. 2021;38(1):423-440.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. Reddy KR, Hassanein T, Jacobson IM, et al., eds. N Engl J Med. 2014;370(3):211-221.
Sulkowski MS, Eron JJ, Wyles DL, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223-1231.
Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202-1204.
Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161-4167.
Suryaprasad AG, White JZ, Xu F. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;(59):1411-1419.
Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Hebner C, Gontcharova V, Martin R, et al., eds. Clin Infect Dis. 2014;59(12):1666-1674.
Svoboda J, Andreadis C, Downs LH, Miller WT, Tsai DE, Schuster SJ. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma. 2005;46(9):1365-1368.
Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593-1601.
Top